|
|
Marketing Authorisations
|
|
|
|
|
Marked reduction in the risk of developing covid-19, and no worrying safety signals
|
|
|
|
|
|
|
|
|
|
|
|
More uncertainty than with subcutaneous liraglutide
|
|
|
|
|
|
|
|
|
|
In the short term, a significant reduction in frequency of attacks
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
Useful for some high-risk patients
|
|
|
|
|
|
|
|
|
|
Survival extended with the addition of apalutamide or enzalutamide
|
|
|
|
|
|
|
|
|
|
|
|
|
|